LUMABS BV
Diagnostic Tests & IVD · Health Care
Overview
About Us Work on What Matters At LUMABS BV, we are driven by a clear mission: to advance quantitative antibody detection.
Funding and backers
Team
1-10
employees, estimated range
Backers
1
NLC Health Ventures
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
Tractionpublic signals, read monthly
Web presence
top 40%
of 133.2M domains by links, Common Crawl
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Home About Us About us Abionic, an emerging medical diagnostics company focused on rapid early detection technologies, received 510(k)…
Age Labs is a Norwegian life science company that discovers, develops and commercializes diagnostic tests for the early detection of…
" " Empowering Your Health Journey The catalyst in your journey towards self improvement and better health monitoring Our Story We started…
Biograph specializes in longevity health and early disease detection, with advanced diagnostics offered at our New York and San Francisco…
Revolutionizing Healthcare Through Better Insight. Better treatment starts with more timely and more precise detection, at the very…
We are redefining digestive health by pioneering non-endoscopic diagnostics, enabling early detection of diseases and access to care for…
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
NLC Health VenturesVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Poster Session EMCHD 2026
Our collaborative work with Sanquin was recently presented as a poster at EMCHD 2026 in Cardiff. The poster, titled "Next-generation Immunoassay: RAPPID-CompAct," highlights our latest work on C3b detection using the RAPPID-CompAct platform. We are proud
Read more
Report
Two abstracts accepted for poster presentation at GAMRIC 2026
We are pleased to announce that two abstracts have been accepted for poster presentation at GAMRIC 2026, both within the track AMR Diagnostics. The first abstract, "Fast, Sensitive, and Specific Detection of Ambler Class A, B, and D Carbapenemases using a
Read more
Report
Looking back at ESCMID Global 2026, Munich
At the ESCMID Global congress, we had the opportunity to present our latest findings during the poster session. And we're proud to share that our poster: 'Towards point-of-care' detection of Staphylococcus Aureus in synovial fluid using the RAPPID technol
Read more
Report
LUMABS at ESCMID
We are pleased to announce that an abstract from LUMABS BV collaboration with UMCG, TU/e and SABIAD BV has been accepted for poster presentation at the ESCMID conference, Munich 2026. We look forward to sharing our latest work with the scientific communit
Read more
Report
Project Visit: Health & Innovation District Amsterdam (HID)
On November 14, Kansen voor West visited the Health & Innovation District Amsterdam (HID) at Sanquin. HID provides SMEs and start-ups access to research facilities normally reserved for larger institutions, helping accelerate innovation in red biotech. Du
Read more
Report
New Generation of RAPPID Sensor
LUMABS BV is proud to highlight the latest RAPPID development from our founding scientist team, the Merkx Lab. The new RAPPID-M sensor replaces protein G with protein M440 (pM440), creating a mix-and-measure bioluminescent assay with exciting improvements
Read more
Report